Table 1.

Patient, donor, and graft characteristics

No. patients 116* 
Median patient age (range) 38 yrs (17-61)  
Patient sex (male/female) 58/58 
Diagnosis  
 Leukemia/myelodysplastic syndrome 66 
 Lymphoma/Hodgkin disease/myeloma 42  
 Solid tumor 
Disease status  
 First remission or chronic phase 12 
 Second remission or accelerated phase 31  
 Relapse or blast crisis 73  
Preparative regimen  
 Total body irradiation–based 30  
 Chemotherapy alone 86  
GVHD prophylaxis  
 Cyclosporine/methylprednisolone 32 
 Tacrolimus/methylprednisolone 45 
 Tacrolimus/methotrexate 39  
Prior grades 2-4 acute GVHD 33  
On steroids at day 100 46  
Median donor age (range) 39 yrs (8-64)  
Donor sex (male/female) 57/59  
Pair cytomegalovirus-seronegative 12  
Total nucleated cells infused (range) 8.7 × 108/kg (1.1-26.3) 
CD34+ cells infused (range) 5.7 × 106/kg (1.9-20.9)  
CD3+ cells infused (range) 2.3 × 108/kg (0.3-6.9)  
CD56+cells infused (range) 2.6 × 107/kg (1.0-8.1) 
No. patients 116* 
Median patient age (range) 38 yrs (17-61)  
Patient sex (male/female) 58/58 
Diagnosis  
 Leukemia/myelodysplastic syndrome 66 
 Lymphoma/Hodgkin disease/myeloma 42  
 Solid tumor 
Disease status  
 First remission or chronic phase 12 
 Second remission or accelerated phase 31  
 Relapse or blast crisis 73  
Preparative regimen  
 Total body irradiation–based 30  
 Chemotherapy alone 86  
GVHD prophylaxis  
 Cyclosporine/methylprednisolone 32 
 Tacrolimus/methylprednisolone 45 
 Tacrolimus/methotrexate 39  
Prior grades 2-4 acute GVHD 33  
On steroids at day 100 46  
Median donor age (range) 39 yrs (8-64)  
Donor sex (male/female) 57/59  
Pair cytomegalovirus-seronegative 12  
Total nucleated cells infused (range) 8.7 × 108/kg (1.1-26.3) 
CD34+ cells infused (range) 5.7 × 106/kg (1.9-20.9)  
CD3+ cells infused (range) 2.3 × 108/kg (0.3-6.9)  
CD56+cells infused (range) 2.6 × 107/kg (1.0-8.1) 
*

No. patients unless indicated otherwise.

Close Modal

or Create an Account

Close Modal
Close Modal